ＦＳＴＬ１タンパク質を有効成分として含有する、癌または癌転移の予防及び治療用の薬学的組成物

Japanese Patent JP6621544

B2

The present invention relates to a pharmaceutical composition for preventing and treating cancer, cancer metastasis and bone metabolic diseases, which comprises FSTL1 (Follistatin-like 1) protein as an active ingredient. More specifically, FSTL1 inhibits AKT activity and increases activity of tumor suppressor protein PTEN (phosphatase and tensin homolog deleted on chromosome 10), while inhibiting DNA binding of NF-ºB (nuclear factor-ºB) and blocking the expression of target genes IL-6, GM -CSF, MMP-9, VEGF and ICAM1, and exhibits significant inhibitory effects on breast cancer growth and metastasis in animal models. Therefore, it can be useful for inhibiting cancer metastasis including breast cancer.

WO/2022/016308	MAVS PROTEIN DEGRADATION INHIBITOR AND USE THEREOF
WO/2003/048202	NF-KAPPAB ACTIVATING GENES
WO/2000/071096	METHODS AND COMPOSITIONS FOR NON-VIRAL GENE THERAPY FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES

PARK, Bae Keun

JP2018545791A

December 18, 2019

November 18, 2016

Click for automatic bibliography generation  

METACINE, INC.

A61K38/17; A23L33/17; A61K35/13; A61K35/15; A61K35/28; A61K35/76; A61K35/761; A61K35/763; A61K48/00; A61P19/00; A61P35/00; A61P35/04; A61P43/00; G01N33/15; G01N33/50; G01N33/68

Carcinogenesis,2009年,Vol.30,No.1,p. 114-121
ARTHRITIS & RHEUMATISM,2004年,Vol.50,No.2,p.660-668

sk patent corporation
Akihiko Okuno
Hiroyuki Ito

Previous Patent: ハイブリッドアプリケーションの自動更新

Next Patent: 電気刺激装置